



UNITED STATES PATENT AND TRADEMARK OFFICE

416

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/018,314	05/22/2002	Bradford A Jameson	MCP-0054	1642
26259	7590	10/19/2004		
LICATLA & TYRRELL P.C. 66 E. MAIN STREET MARLTON, NJ 08053				
			EXAMINER VANDERVEGT, FRANCOIS P	
			ART UNIT	PAPER NUMBER
			1644	

DATE MAILED: 10/19/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Art Unit: 1644

DETAILED ACTION

This application is a rule 371 continuation of PCT Serial Number PCT/US00/11902; which claims the benefit of the filing date of provisional applications 60/132,361, 60/150,150 and 60/162,632.

Claims 1-3 are currently pending.

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1, drawn to a composition comprising a compound that mimics or interacts with a surface feature of a CD8/MHC class I molecule complex.

Group II, claim(s) 2, drawn to a method for producing a compound that inhibits a detrimental cytotoxic T cell response, wherein said compound that mimics or interacts with a surface feature of a CD8/MHC class I molecule complex.

Group III, claim(s) 3, drawn to a method of inhibiting a detrimental cytotoxic T cell response comprising administering a compound that mimics or interacts with a surface feature of a CD8/MHC class I molecule complex.

2. The inventions listed as Groups I-III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The claim of Group I is broadly drawn to any compound that can inhibit a detrimental cytotoxic T cell response by interacting with any part of the CD8/MHC class I complex. The term "detrimental" is open to reading upon any response that is not desired. VanderVegt et al (J. Exp. Med. [1993] 177:1587-1592; U on form PTO-892) teaches that transient treatment of female mice with an anti-CD8 monoclonal antibody prevents rejection of male tissue grafts based upon recognition of minor histocompatibility antigens (Abstract in particular). Accordingly, the prior art teaches a compound that interacts with CD8 and inhibits a detrimental cytotoxic T cell response. The claims are not therefore linked by a special technical feature so as to constitute a single inventive concept.

3. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Art Unit: 1644

4. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to F. Pierre VanderVegt whose telephone number is (571) 272-0852. The examiner can normally be reached on M-Th 6:30-4:00; Alternate Fridays 6:30-3:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (571) 272-0841. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

F. Pierre VanderVegt, Ph.D. *RV*
Patent Examiner
October 5, 2004

Pat. J. Nolan
PATRICK J. NOLAN, PH.D.
PRIMARY EXAMINER
10/13/04